NEUNEUREN PHARMACEUTICALS LIMITED

H1 2025 profit after tax A$15m, up from A$8m in H1 2024

Date and time
Announcement type
Financial Results

More from Health Care

More News

ARLCompany Update12 November 2026

Ardea Resources (ASX: ARL) Scandium Study Models US$510m NPV